LivaNova LIVN Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Business | ||||||
| Cardiopulmonary | $817.72M+16.2% | $785.39M+14.9% | $760.48M+14.0% | $729.5M+13.3% | $703.94M+12.8% | |
| Neuromodulation | $605.71M+8.3% | $592.81M+7.0% | $577.7M+4.4% | $568.04M+4.7% | $559.24M+5.0% | |
| Operating Income by Business | ||||||
| Cardiopulmonary | $113.68M— | $108.3M— | $101.64M— | $98.61M— | —— | |
| Neuromodulation | $207.28M— | $215.47M— | $208.84M— | $202.19M— | —— | |
| Total Assets by Business | ||||||
| Cardiopulmonary | $4.12B+10.2% | $4.02B+7.3% | $3.87B+1.8% | $3.82B+1.3% | $3.74B-0.2% | |
| Neuromodulation | $2.57B+0.4% | $2.56B-0.3% | $2.56B-0.5% | $2.56B-1.0% | $2.56B-1.0% | |
| Selling, general, and administrative by Business | ||||||
| Cardiopulmonary | $231.15M+0.9% | $229.78M+3.8% | $243.37M+20.0% | $234.12M+14.1% | $229.05M+11.2% | |
| Neuromodulation | $207.65M+9.6% | $202.6M+8.0% | $198.93M+9.8% | $194.52M+8.4% | $189.53M+7.0% | |
| Cost of Sales by Business | ||||||
| Cardiopulmonary | $397.72M+16.0% | $381.71M+14.2% | $368.94M+15.1% | $351.83M+11.3% | $342.97M+12.1% | |
| Neuromodulation | $56.65M+6.3% | $55.82M+11.1% | $57.17M+23.0% | $55.86M+17.3% | $53.29M+11.1% | |
| R&D by Business | ||||||
| Cardiopulmonary | $71.49M+34.9% | $65.74M+24.3% | $61.18M+23.2% | $55.63M+14.9% | $53M+15.5% | |
| Neuromodulation | $134.13M+16.2% | $118.92M-1.7% | $112.76M-13.0% | $115.46M-12.1% | $115.44M-15.6% | |
| 3T litigation provision by Business | ||||||
| Cardiopulmonary | $3.69M-73.7% | $4.38M-77.8% | $7.26M-71.4% | $11.22M-57.4% | $14M-56.6% | |
| Neuromodulation | $0— | $0— | $0— | $0— | $0— | |
| CapEx by Business | ||||||
| Cardiopulmonary | $49.75M+68.6% | $44.51M+58.4% | $32.86M+11.3% | $30.75M+16.9% | $29.51M+38.4% | |
| Neuromodulation | $22.64M+277% | $15.83M+273% | $12.85M+416% | $9.49M+455% | $6M+437% | |
| Goodwill by Business | ||||||
| Cardiopulmonary | $1.57B+7.0% | $1.54B+4.7% | $1.5B-0.4% | $1.49B-0.1% | $1.46B-2.7% | |
| Neuromodulation | $1.6B0.0% | $1.6B0.0% | $1.6B0.0% | $1.6B0.0% | $1.6B0.0% | |
| Net revenue by Geography | ||||||
| Europe | $285.13M+26.5% | $269.18M+22.3% | $255.78M+15.7% | $240.91M+11.4% | $225.39M+2.7% | |
| Rest of World | $393.24M+13.5% | $379.3M+12.1% | $370M+13.0% | $355.86M+11.7% | $346.36M+11.7% | |
| United States | $755.09M+7.3% | $739.57M+6.4% | $723.18M+4.3% | $712.56M+5.6% | $703.63M+7.4% | |
| Property, Plant and Equipment, Net by Geography | ||||||
| Europe | $540.14M+46.6% | $487.95M+39.2% | $435.04M+27.3% | $394.99M+19.8% | $368.33M+13.4% | |
| Rest of World | $61.45M+77.9% | $56.46M+95.4% | $51.35M+113% | $43.18M+96.8% | $34.54M+71.2% | |
| United States | $310.43M+13.9% | $289.81M+7.1% | $275.48M+2.8% | $274.51M+4.8% | $272.45M+4.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does LivaNova break its business down?
- LivaNova (LIVN) reports net revenue by business across 2 parts — Cardiopulmonary and Neuromodulation. Each is extracted from the segment footnotes and tracked over time.
- Where does LivaNova's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in LivaNova's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.